HK Stock MarketDetailed Quotes

CANSINOBIO (06185)

Watchlist
  • 28.220
  • -0.560-1.95%
Market Closed May 7 16:07 CST
6.97BMarket Cap-5644.00P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

CANSINOBIO (06185) Income Statement

All
YOY yoy
Hide blank lines yoy
(Q1)Mar 31, 2026
(FY)Dec 31, 2025
(Q9)Sep 30, 2025
(Q6)Jun 30, 2025
(Q1)Mar 31, 2025
(FY)Dec 31, 2024
(Q9)Sep 30, 2024
(Q6)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
Turnover
38.73%190.28M
28.43%1.06B
22.13%692.57M
31.07%374.09M
20.02%137.16M
138.97%824.88M
222.88%567.08M
1,253.60%285.42M
13.65%114.28M
-66.52%345.18M
Operating income
38.73%190.28M
28.43%1.06B
22.13%692.57M
31.07%374.09M
20.02%137.16M
138.97%824.88M
222.88%567.08M
1,253.60%285.42M
13.65%114.28M
-66.52%345.18M
Cost of sales
----
-6.42%-260.13M
----
21.13%-77.51M
----
79.98%-244.43M
----
87.68%-98.27M
----
-0.29%-1.22B
Operating expenses
-52.72%-36.26M
-6.42%-260.13M
8.50%-133.86M
21.13%-77.51M
48.64%-23.74M
79.98%-244.43M
15.30%-146.28M
87.68%-98.27M
29.08%-46.23M
-0.29%-1.22B
Gross profit
35.80%154.02M
37.70%799.26M
32.78%558.71M
58.47%296.58M
66.67%113.42M
166.26%580.45M
14,344.25%420.79M
124.10%187.15M
92.41%68.05M
-369.45%-876.02M
Selling expenses
-38.21%-81.08M
-12.92%-416.73M
-41.41%-277.22M
-39.00%-156.34M
-25.92%-58.66M
-4.43%-369.05M
-1.24%-196.04M
12.70%-112.48M
15.27%-46.59M
-32.55%-353.4M
Administrative expenses
-2.30%-35.77M
10.93%-173.11M
6.29%-110.05M
11.41%-77.76M
5.66%-34.97M
33.99%-194.36M
37.57%-117.43M
37.33%-87.78M
38.78%-37.07M
-5.89%-294.45M
Research and development expenses
1.79%-71.41M
24.77%-313.04M
17.48%-224.67M
20.50%-147.79M
24.84%-72.71M
34.78%-416.12M
41.02%-272.27M
45.06%-185.9M
35.40%-96.75M
18.02%-637.99M
Profit from asset sales
----
----
281.80%42.96K
----
--84.72K
----
-163.08%-23.63K
----
----
----
Revaluation surplus
7.93%2.91M
----
157.01%4.1M
----
229.10%2.7M
----
53.23%-7.19M
----
-129.16%-2.09M
----
-Changes in the fair value of other assets
7.93%2.91M
----
157.01%4.1M
----
229.10%2.7M
----
53.23%-7.19M
----
-129.16%-2.09M
----
Impairment and provision
56.90%-4.66M
17.40%-12.52M
-9.52%-26.18M
12.12%-12.36M
28.24%-10.8M
-0.70%-15.15M
97.02%-23.9M
30.59%-14.06M
-16.94%-15.05M
-71.43%-15.05M
-Other impairment is provision
56.90%-4.66M
17.40%-12.52M
-9.52%-26.18M
12.12%-12.36M
28.24%-10.8M
-0.70%-15.15M
97.02%-23.9M
30.59%-14.06M
-16.94%-15.05M
-71.43%-15.05M
Special items of operating profit
-71.99%14.16M
1,379.74%160.39M
601.99%115.54M
355.24%95.46M
175.68%50.55M
-92.35%10.84M
-113.76%-23.02M
-160.73%-37.4M
-230.88%-66.79M
-5.26%141.72M
Operating profit
-98.20%-25.08M
110.97%44.26M
113.15%29.72M
99.12%-2.21M
93.62%-12.66M
80.18%-403.39M
84.89%-225.94M
81.34%-250.47M
-6.28%-198.26M
-48.69%-2.04B
Financing income
-22.37%7.84M
-57.78%34.77M
-53.43%23.9M
-67.97%17.33M
-56.90%10.1M
-31.74%82.35M
-31.75%51.32M
-38.87%54.09M
4.06%23.43M
-46.75%120.64M
Financing cost
44.77%-7.19M
4.77%-57.29M
23.21%-36.4M
-4.87%-34.42M
11.29%-13.02M
6.50%-60.16M
-3.15%-47.41M
-11.65%-32.82M
-67.46%-14.67M
-53.82%-64.34M
Special items of earning before tax
63.39%-40.92K
----
82.44%-504.64K
----
-6,398.83%-111.76K
----
92.94%-2.87M
----
99.98%-1.72K
----
Earning before tax
-107.18%-34.38M
105.70%21.74M
103.76%8.49M
91.58%-19.3M
90.51%-16.59M
80.74%-381.2M
84.50%-225.7M
82.14%-229.2M
12.76%-174.88M
-67.14%-1.98B
Tax
----
348.68%6.14M
----
703.53%5.82M
----
-121.54%-2.47M
----
-182.82%-964K
----
-94.78%11.45M
After-tax profit from continuing operations
-250.13%-40.42M
107.26%27.87M
106.36%14.44M
94.14%-13.49M
93.40%-11.55M
80.50%-383.67M
84.38%-227.2M
82.05%-230.16M
-2.75%-174.88M
-103.93%-1.97B
Earning after tax
-250.13%-40.42M
107.26%27.87M
106.36%14.44M
94.14%-13.49M
93.40%-11.55M
80.50%-383.67M
84.38%-227.2M
82.05%-230.16M
-2.75%-174.88M
-103.93%-1.97B
Minority profit
----
----
----
----
----
99.01%-4.79M
98.98%-4.79M
98.91%-4.79M
84.38%-4.79M
-776.08%-484.7M
Profit attributable to shareholders
-250.13%-40.42M
107.36%27.87M
106.49%14.44M
94.02%-13.49M
93.21%-11.55M
74.45%-378.88M
77.42%-222.41M
73.22%-225.37M
-21.89%-170.1M
-63.04%-1.48B
Basic earnings per share
-220.00%-0.16
107.19%0.11
106.67%0.06
94.51%-0.05
92.75%-0.05
74.54%-1.53
77.44%-0.9
73.31%-0.91
-21.05%-0.69
-63.32%-6.01
Diluted earnings per share
-220.00%-0.16
107.19%0.11
106.67%0.06
94.51%-0.05
92.75%-0.05
74.54%-1.53
77.44%-0.9
73.31%-0.91
-21.05%-0.69
-63.32%-6.01
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
Audit Opinions
--
Unqualified Opinion
--
--
--
Unqualified Opinion
--
--
--
Unqualified Opinion
Auditor
--
Deloitte Touche Tohmatsu Limited, Deloitte China CPA Firm (Special General Partnership)
--
--
--
Deloitte Touche Tohmatsu Limited, Deloitte China CPA Firm (Special General Partnership)
--
--
--
Deloitte Touche Tohmatsu Limited, Deloitte China CPA Firm (Special General Partnership)
(Q1)Mar 31, 2026(FY)Dec 31, 2025(Q9)Sep 30, 2025(Q6)Jun 30, 2025(Q1)Mar 31, 2025(FY)Dec 31, 2024(Q9)Sep 30, 2024(Q6)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023
Turnover 38.73%190.28M28.43%1.06B22.13%692.57M31.07%374.09M20.02%137.16M138.97%824.88M222.88%567.08M1,253.60%285.42M13.65%114.28M-66.52%345.18M
Operating income 38.73%190.28M28.43%1.06B22.13%692.57M31.07%374.09M20.02%137.16M138.97%824.88M222.88%567.08M1,253.60%285.42M13.65%114.28M-66.52%345.18M
Cost of sales -----6.42%-260.13M----21.13%-77.51M----79.98%-244.43M----87.68%-98.27M-----0.29%-1.22B
Operating expenses -52.72%-36.26M-6.42%-260.13M8.50%-133.86M21.13%-77.51M48.64%-23.74M79.98%-244.43M15.30%-146.28M87.68%-98.27M29.08%-46.23M-0.29%-1.22B
Gross profit 35.80%154.02M37.70%799.26M32.78%558.71M58.47%296.58M66.67%113.42M166.26%580.45M14,344.25%420.79M124.10%187.15M92.41%68.05M-369.45%-876.02M
Selling expenses -38.21%-81.08M-12.92%-416.73M-41.41%-277.22M-39.00%-156.34M-25.92%-58.66M-4.43%-369.05M-1.24%-196.04M12.70%-112.48M15.27%-46.59M-32.55%-353.4M
Administrative expenses -2.30%-35.77M10.93%-173.11M6.29%-110.05M11.41%-77.76M5.66%-34.97M33.99%-194.36M37.57%-117.43M37.33%-87.78M38.78%-37.07M-5.89%-294.45M
Research and development expenses 1.79%-71.41M24.77%-313.04M17.48%-224.67M20.50%-147.79M24.84%-72.71M34.78%-416.12M41.02%-272.27M45.06%-185.9M35.40%-96.75M18.02%-637.99M
Profit from asset sales --------281.80%42.96K------84.72K-----163.08%-23.63K------------
Revaluation surplus 7.93%2.91M----157.01%4.1M----229.10%2.7M----53.23%-7.19M-----129.16%-2.09M----
-Changes in the fair value of other assets 7.93%2.91M----157.01%4.1M----229.10%2.7M----53.23%-7.19M-----129.16%-2.09M----
Impairment and provision 56.90%-4.66M17.40%-12.52M-9.52%-26.18M12.12%-12.36M28.24%-10.8M-0.70%-15.15M97.02%-23.9M30.59%-14.06M-16.94%-15.05M-71.43%-15.05M
-Other impairment is provision 56.90%-4.66M17.40%-12.52M-9.52%-26.18M12.12%-12.36M28.24%-10.8M-0.70%-15.15M97.02%-23.9M30.59%-14.06M-16.94%-15.05M-71.43%-15.05M
Special items of operating profit -71.99%14.16M1,379.74%160.39M601.99%115.54M355.24%95.46M175.68%50.55M-92.35%10.84M-113.76%-23.02M-160.73%-37.4M-230.88%-66.79M-5.26%141.72M
Operating profit -98.20%-25.08M110.97%44.26M113.15%29.72M99.12%-2.21M93.62%-12.66M80.18%-403.39M84.89%-225.94M81.34%-250.47M-6.28%-198.26M-48.69%-2.04B
Financing income -22.37%7.84M-57.78%34.77M-53.43%23.9M-67.97%17.33M-56.90%10.1M-31.74%82.35M-31.75%51.32M-38.87%54.09M4.06%23.43M-46.75%120.64M
Financing cost 44.77%-7.19M4.77%-57.29M23.21%-36.4M-4.87%-34.42M11.29%-13.02M6.50%-60.16M-3.15%-47.41M-11.65%-32.82M-67.46%-14.67M-53.82%-64.34M
Special items of earning before tax 63.39%-40.92K----82.44%-504.64K-----6,398.83%-111.76K----92.94%-2.87M----99.98%-1.72K----
Earning before tax -107.18%-34.38M105.70%21.74M103.76%8.49M91.58%-19.3M90.51%-16.59M80.74%-381.2M84.50%-225.7M82.14%-229.2M12.76%-174.88M-67.14%-1.98B
Tax ----348.68%6.14M----703.53%5.82M-----121.54%-2.47M-----182.82%-964K-----94.78%11.45M
After-tax profit from continuing operations -250.13%-40.42M107.26%27.87M106.36%14.44M94.14%-13.49M93.40%-11.55M80.50%-383.67M84.38%-227.2M82.05%-230.16M-2.75%-174.88M-103.93%-1.97B
Earning after tax -250.13%-40.42M107.26%27.87M106.36%14.44M94.14%-13.49M93.40%-11.55M80.50%-383.67M84.38%-227.2M82.05%-230.16M-2.75%-174.88M-103.93%-1.97B
Minority profit --------------------99.01%-4.79M98.98%-4.79M98.91%-4.79M84.38%-4.79M-776.08%-484.7M
Profit attributable to shareholders -250.13%-40.42M107.36%27.87M106.49%14.44M94.02%-13.49M93.21%-11.55M74.45%-378.88M77.42%-222.41M73.22%-225.37M-21.89%-170.1M-63.04%-1.48B
Basic earnings per share -220.00%-0.16107.19%0.11106.67%0.0694.51%-0.0592.75%-0.0574.54%-1.5377.44%-0.973.31%-0.91-21.05%-0.69-63.32%-6.01
Diluted earnings per share -220.00%-0.16107.19%0.11106.67%0.0694.51%-0.0592.75%-0.0574.54%-1.5377.44%-0.973.31%-0.91-21.05%-0.69-63.32%-6.01
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards CAS (2007)HKASCAS (2007)HKASCAS (2007)HKASCAS (2007)HKASCAS (2007)HKAS
Audit Opinions --Unqualified Opinion------Unqualified Opinion------Unqualified Opinion
Auditor --Deloitte Touche Tohmatsu Limited, Deloitte China CPA Firm (Special General Partnership)------Deloitte Touche Tohmatsu Limited, Deloitte China CPA Firm (Special General Partnership)------Deloitte Touche Tohmatsu Limited, Deloitte China CPA Firm (Special General Partnership)

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
Petroleum
No. Symbol 20D % Chg
Sample Name
Sample Code
 +3.10%
Sample Name
Sample Code
 +2.18%
Sample Name
Sample Code
 +1.23%
4
CNOOC
00883
+1.15%
5
SINOPEC CORP
00386
-1.48%
View More
No. Symbol 20D % Chg
Sample Name
Sample Code
 +68.99%
Sample Name
Sample Code
 +59.23%
Sample Name
Sample Code
 +44.37%
4
Emdoor Information
001314
+43.99%
5
Digital China Group
000034
+29.13%
View More
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -